EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between Artiva Biotherapeutics, Inc. and Merck Sharp & Dohme Corp.Exclusive License and Research Collaboration Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License and Research Collaboration Agreement (this “Agreement”) is effective as of January 27, 2021 (the “Effective Date”) and is entered into by and between Artiva Biotherapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Company”) and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”).
ANDExclusive License and Research Collaboration Agreement • March 6th, 2007 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between YUMANITY THERAPEUTICS INC. and MERCK SHARP & DOHME CORP.Exclusive License and Research Collaboration Agreement • October 28th, 2020 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • New York
This Agreement (this “Agreement”) is effective as of June 19, 2020, (the “Effective Date”) and is entered into by and between YUMANITY THERAPEUTICS INC., a corporation organized and existing under the laws of Delaware (“Company”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”).
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between MERCK & CO., INC. and SURMODICS, INC.Exclusive License and Research Collaboration Agreement • August 9th, 2007 • Surmodics Inc • Patent owners & lessors • New York
* Portions omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.
